|
Patent landscape, scope, and claims: |
United States Patent 5,010,070: Scope, Claim Structure, and US Landscape for Multiphase Contraceptive Kits
What does US Patent 5,010,070 claim, in plain scope terms?
US 5,010,070 claims a multiphase, daily-dosage contraceptive kit built as a package containing multiple phases (I to III) of norethindrone acetate + ethinyl estradiol tablets or “compositions,” with stepwise increases in ethinyl estradiol across phases. The patent also claims an optional Phase IV addition of ferrous fumarate (iron) as part of the kit.
The core claim theme is not a new steroid molecule. It is the specific multiphase product architecture (multiple phases in one package) and specific stepwise EE (ethinyl estradiol) escalation patterns, combined with a defined norethindrone acetate range and (in dependent claims) specific phase counts and specific numeric exemplars.
Independent claim: product and escalation mechanics (Claim 1)
Claim 1 requires a kit with:
- A package containing daily dosages of three compositions:
- Phase I: about 0.5 to 1.5 mg norethindrone acetate and about 10 to 50 mcg ethinyl estradiol
- Phase II: about 0.5 to 1.5 mg norethindrone acetate and about 10 to 50 mcg ethinyl estradiol
- Phase III: about 0.5 to 1.5 mg norethindrone acetate and about 10 to 50 mcg ethinyl estradiol
- The amount of ethinyl estradiol is increased stepwise over the three compositions.
Interpretation for design-around and claim reach
- “Stepwise increased” means EE is higher in Phase II than Phase I and higher in Phase III than Phase II (or at least a monotonic escalation across phases).
- The EE endpoints can still fall within the broad 10-50 mcg range per phase, but the comparative order is required.
Dependent claims: adding iron (Claims 2–3)
- Claim 2: Claim 1 kit additionally comprises a Phase IV composition containing ferrous fumarate.
- Claim 3: Phase IV ferrous fumarate is about 75 mg.
This builds in the classic “iron supplement” addition common to some extended or multiphase regimens, and it narrows the iron form and dose in the dependent claims.
Second independent claim structure: dosing schedules and tighter EE ranges (Claims 4–6)
Claim 4 again claims a multiphase kit, but it is schedule-defined:
- Package contains daily dosages split into:
- Phase I: about 4 to 7 dosages
- Phase II: about 5 to 8 dosages
- Phase III: about 7 to 12 dosages
- Each phase has defined EE windows that are narrower than Claim 1’s broad 10–50 mcg:
- Phase I EE: about 10 to 30 mcg
- Phase II EE: about 20 to 40 mcg
- Phase III EE: about 30 to 50 mcg
- EE again increases stepwise over the three compositions.
- Norethindrone acetate stays broad in this claim:
- about 0.5 to 1.5 mg in each phase.
Claim 5 adds:
- about 9 dosages of Phase IV ferrous fumarate.
Claim 6 specifies:
- Phase IV ferrous fumarate is about 75 mg.
Exemplar-specific dependent claim variations (Claims 7–12)
These claims lock in specific numeric formulations and specific counts:
Claim 7:
- Phase I: 1.0 mg norethindrone acetate + 20 mcg EE
- Phase II: 1.0 mg norethindrone acetate + 30 mcg EE
- Phase III: 1.0 mg norethindrone acetate + 40 mcg EE
Claim 8 (counts):
- about 5 Phase I dosages
- about 7 Phase II dosages
- about 9 Phase III dosages
Claim 9:
- Phase I: 1.0 mg norethindrone acetate + 20 mcg EE
- Phase II: 1.5 mg norethindrone acetate + 30 mcg EE
- Phase III: 1.0 mg norethindrone acetate + 50 mcg EE
Claim 10 (counts):
- about 5 Phase I dosages
- about 7 Phase II dosages
- about 9 Phase III dosages
Claim 11:
- Phase I: 1.0 mg norethindrone acetate + 20 mcg EE
- Phase II: 1.0 mg norethindrone acetate + 30 mcg EE
- Phase III: 1.0 mg norethindrone acetate + 35 mcg EE
Claim 12 (counts):
- about 5 Phase I dosages
- about 7 Phase II dosages
- about 9 Phase III dosages
How broad are the claims, and where are the hard boundaries?
A. EE step-up is the essential limitation
All claims share the escalation concept:
- “Amount of ethinyl estradiol is increased stepwise over the three compositions.”
This is the main differentiator versus single-dose constant EE regimens.
B. Norethindrone acetate is broad in the independent claims, narrower in the exemplars
- Claim 1: 0.5–1.5 mg per phase.
- Claim 4: 0.5–1.5 mg per phase.
- Claim 7/11: “fixed” 1.0 mg in Phases I–III.
- Claim 9: varies to 1.5 mg in Phase II.
C. EE per-phase windows differ between Claim 1 and Claim 4
- Claim 1: 10–50 mcg EE allowed in each phase, with the stepwise increase order controlling.
- Claim 4: EE is structured into narrower banding:
- Phase I: 10–30
- Phase II: 20–40
- Phase III: 30–50
This creates an internal coupling between phase identity and EE dose bands.
D. Phase counts become additional limitations in Claim 4 and dependent claims
- Claim 4 adds how many daily dosages come from each phase:
- Phase I: 4–7
- Phase II: 5–8
- Phase III: 7–12
- Claims 8, 10, 12 further fix counts at 5 / 7 / 9.
E. Phase IV iron is optional at the independent level, then fixed in dependents
- Claim 1 does not require iron.
- Claim 2 requires ferrous fumarate.
- Claim 3 requires about 75 mg ferrous fumarate.
- Claims 5–6 similarly fix the number of Phase IV doses and dose strength.
Claim-by-claim scope map (what you would potentially infringe)
| Claim |
Required kit elements |
Steroid ranges / values |
Phase IV iron |
Phase counts limitations |
| 1 |
Phase I + II + III daily dosing; EE increases stepwise |
NEA: ~0.5–1.5 mg each phase; EE: ~10–50 mcg each phase; EE escalates across phases |
Not required |
Not specified |
| 2 |
Claim 1 + Phase IV ferrous fumarate |
Same as Claim 1 |
Required; ferrous fumarate present |
Not specified |
| 3 |
Claim 2 + ferrous fumarate dose |
Same as Claim 1 |
~75 mg ferrous fumarate |
Not specified |
| 4 |
Phase I/II/III daily dosing with specific EE bands and phase counts |
NEA: ~0.5–1.5 mg each phase; EE bands: I ~10–30, II ~20–40, III ~30–50; EE escalates |
Optional (only via dependency chain to 5/6) |
Phase I: ~4–7; Phase II: ~5–8; Phase III: ~7–12 |
| 5 |
Claim 4 + Phase IV |
Same as Claim 4 |
Ferrous fumarate present; ~9 Phase IV dosages |
Phase counts for I–III already set by Claim 4 |
| 6 |
Claim 5 + iron dose |
Same as Claim 4 |
~75 mg ferrous fumarate |
Phase counts for I–III already set by Claim 4 |
| 7 |
Claim 4 subclass with fixed EE/NEA per phase |
Phase I: NEA 1.0 mg + EE 20 mcg; Phase II: NEA 1.0 mg + EE 30 mcg; Phase III: NEA 1.0 mg + EE 40 mcg |
Not stated (implied by dependency only if tied to Claim 4 chain) |
Not stated |
| 8 |
Claim 7 + fixed phase dosage counts |
Same as Claim 7 |
Not stated |
Phase I ~5, Phase II ~7, Phase III ~9 |
| 9 |
Claim 4 subclass with one different NEA and EE values |
Phase I: NEA 1.0 mg + EE 20 mcg; Phase II: NEA 1.5 mg + EE 30 mcg; Phase III: NEA 1.0 mg + EE 50 mcg |
Not stated |
Not stated |
| 10 |
Claim 9 + fixed phase dosage counts |
Same as Claim 9 |
Not stated |
Phase I ~5, Phase II ~7, Phase III ~9 |
| 11 |
Claim 4 subclass with different Phase III EE |
Phase I: NEA 1.0 mg + EE 20 mcg; Phase II: NEA 1.0 mg + EE 30 mcg; Phase III: NEA 1.0 mg + EE 35 mcg |
Not stated |
Not stated |
| 12 |
Claim 11 + fixed phase dosage counts |
Same as Claim 11 |
Not stated |
Phase I ~5, Phase II ~7, Phase III ~9 |
What is the practical “product form” the claims cover?
Kit format
- A single package containing daily dosages for multiple phases.
- The claims do not require specific blister configuration, tablet identification, or explicit labeling text, only that the kit “contains daily dosages” of the defined compositions.
Tablet strength and regimen structure
- The composition of each phase is defined by (i) norethindrone acetate amount and (ii) ethinyl estradiol amount.
- The regimen structure is defined by:
- three phase EE escalation (Claims 1, 4),
- additional phase counts (Claim 4 and dependents),
- optional ferrous fumarate Phase IV (Claims 2–3 and 5–6).
US patent landscape: where this sits vs likely prior art and adjacent claim space
What this patent is likely targeting
This patent’s claim architecture targets a narrow slice of the broader contraceptive formulation landscape:
- not new hormone classes,
- but multiphase escalating EE systems using norethindrone acetate (and, in some variants, iron placebo or supplementation using ferrous fumarate).
Most relevant adjacent design spaces implied by the claim set
- Constant EE regimens with norethindrone acetate: fall outside stepwise escalation requirement.
- Different escalation patterns:
- EE decreases (excluded by “increased stepwise”),
- EE is constant across phases (excluded),
- EE escalates but outside the phase band constraints of Claim 4 (excluded for that independent claim).
- Different iron forms/doses:
- iron other than ferrous fumarate,
- ferrous fumarate but not ~75 mg,
- different number of Phase IV dosages (fails Claims 5–6).
- Different phase counts:
- even if EE and hormone amounts fit, differing phase dosage counts can avoid Claim 4 and dependents if outside the numeric windows.
Landscape implications for freedom-to-operate (FTO)
- Highest risk is for products that replicate the core architecture:
- norethindrone acetate in the ~0.5–1.5 mg range,
- EE escalating from a Phase I lower band to Phase III higher band,
- and (if included) ferrous fumarate Phase IV at ~75 mg.
- Lower risk is for products that:
- keep EE constant,
- use a different progestin,
- use a different estradiol derivative/dose pattern,
- or omit iron or replace iron dose/form.
Key claim “attack points” for evaluators and litigators
- EE escalation order: must show Phase II EE > Phase I EE and Phase III EE > Phase II EE (for practical claim mapping).
- Phase identity vs numeric band (Claim 4): Phase I must lie in ~10–30 mcg EE; Phase II in ~20–40; Phase III in ~30–50.
- Phase counts (Claim 4 and dependent fixed-count claims): about 4–7, 5–8, 7–12 (or fixed at ~5/7/9 for the exemplars).
- Iron requirement:
- for Claims 2–3: presence of ferrous fumarate and about 75 mg,
- for Claims 5–6: about 9 Phase IV dosages and about 75 mg.
Key Takeaways
- US 5,010,070 claims a norethindrone acetate + ethinyl estradiol multiphase contraceptive kit where EE increases stepwise across Phases I–III.
- The claim set splits risk between:
- broad EE-per-phase allowances with escalation order (Claim 1), and
- structured EE banding plus specific phase dosage counts (Claim 4).
- Dependent claims can require a ferrous fumarate Phase IV at about 75 mg and (in Claim 5/6 lineage) about 9 dosages.
- Exemplar dependents (Claims 7–12) fix specific EE and sometimes norethindrone acetate strengths and set phase dosage counts at about 5 / 7 / 9, tightening infringement mapping for products matching those exact regimens.
FAQs
-
Does the patent require ferrous fumarate?
No. Ferrous fumarate is required only in dependent claims (Claims 2–3 and Claims 5–6). Claim 1 and Claim 4 do not require Phase IV iron.
-
What makes the regimen “covered” at the broadest level?
A package with daily dosages of Phase I, II, III compositions using norethindrone acetate and ethinyl estradiol where ethinyl estradiol is increased stepwise across the three phases.
-
How does Claim 4 differ from Claim 1?
Claim 4 adds phase dosage counts and constrains ethinyl estradiol to phase-specific bands (I ~10–30, II ~20–40, III ~30–50) while still requiring stepwise increase.
-
Are the exemplar dependent claims necessary to infringe?
No. They are narrower. Broad claims (1 and 4) can be implicated even when the product does not match the exact numeric exemplars.
-
Can changing EE within the 10–50 mcg range avoid Claim 1?
It can, if it breaks the required stepwise increase order across Phases I–III or if it fails other claim constraints tied to phase banding and dose counts (especially under Claim 4).
References
[1] US Patent 5,010,070, “Multiphase combination and contraceptive kit,” claims 1-12 (as provided in the prompt).
More… ↓
⤷ Start Trial
|
